StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Botox Cosmetic (onabotulinumtoxinA) by Quarter

Botox Cosmetic (onabotulinumtoxinA) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Botox Cosmetic (onabotulinumtoxinA): 5.2% in Q2 2026, up 10.2 pts from a year earlier.

Latest, Q2 2026
5.2%
Period ended Jun 30, 2026
Change on a year earlier
+10.2 pts
-5.0% in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Botox Cosmetic | 400 | 328 | 728 | (2.4) | 16.4 | 5.2 | 12.1 | 3.4”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBotox Cosmetic (onabotulinumtoxinA) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 20265.2%+10.2 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202620.2%+32.5 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20254.2%+8.4 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025-4.9%-13.1 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-5.0%-11.4 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025-12.3%-8.4 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024-4.2%-16.0 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 20248.2%+10.9 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20246.4%+7.8 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-3.9%-6.8 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202311.8%+9.2 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-2.7%-19.6 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-1.4%-20.3 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20232.9%-31.5 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20222.6%-24.4 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 202216.9%-21.6 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Botox Cosmetic (onabotulinumtoxinA) (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/botox-cosm-ww-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.